CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

Gene therapy represents one of medicine’s most ambitious attempts to treat disease at its root cause by altering the genetic code itself. The approach works by recovering the functions of critical ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene editing will offer a novel therapy for ...

"Traditional gene-editing technologies work best with single mutations and are expensive to optimize, so gene therapies tend to focus on the mutations that are the most common," Buffington said. "But ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...

Sickle-cell disease and β-thalassemia are inherited blood disorders that are caused by mutations in the HBB gene (encoding a component of adult hemoglobin) and are characterized by severe, lifelong ...

The EU has relaxed its rules on gene-editing. Now, only some gene-edited crops are regulated by the stringent GMO directive.

Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.

June studies on NANOG and disease genes highlight potential of base editing and force new discussion on limits of heritable ...

Investments in the cell and gene therapy space have slowed of late. Tome Biosciences says the change is forcing the biotech to make cuts. (Getty Images) After raising $213 million in 2023—one of the ...